MBP134
Experimental cross-species Ebola antibody cocktail; first authorised therapeutic intervention in the 2026 outbreak.
MBP134 became the Bundibugyo outbreak's first authorised treatment on 16 June 2026, and by 16 July had around 60 patients enrolled across its DRC and Uganda trial arms, with results expected around September or October.
Last refreshed: 31 July 2026 · Appears in 1 active topic
Does MBP134's first human trial in the 2026 outbreak signal the end of the MCM gap for non-Zaire Ebola?
Timeline for MBP134
Mentioned in: CEPI puts a Bundibugyo vaccine in trials
Pandemics and BiosecurityAfrica CDC: true cases up to 4x tally
Pandemics and BiosecurityFormed one of four randomised treatment arms alongside remdesivir
Pandemics and Biosecurity: Ebola trial doses its first patientMentioned in: Africa CDC wins direct pandemic funding
Pandemics and BiosecurityEntered first authorised clinical trial as two-antibody treatment arm for Bundibugyo Ebola
Pandemics and Biosecurity: First Ebola treatment trial goes liveBackground
MBP134 is a monoclonal antibody cocktail developed by Mapp Biopharmaceutical, a small San Diego biotech, designed to neutralise multiple ebolavirus species including Bundibugyo, Zaire and Sudan. That breadth addresses the core limitation of the licensed Zaire-only treatments Inmazeb and Ebanga, both validated in the 2018-20 DRC outbreak. In non-human primate studies it gave 100% protection when given up to eight days after infection, a wider window than earlier antibody therapies.
WHO is sponsoring its therapeutic and prophylactic trials in the current outbreak, pairing MBP134 with REGN3479, a Regeneron monoclonal, for treatment, and obeldesivir, an oral prodrug, for post-exposure prophylaxis. The trial protocol needed regulatory sign-off from both DRC and Uganda before any dosing could begin.
As a broadly neutralising, multi-species candidate, MBP134 represents a structurally different approach to Filovirus therapeutics from the single-species Inmazeb, Ebanga and Ervebo: if licensed, it would let responders treat a case before the exact Ebola species is even confirmed, removing a diagnostic delay that has slowed the 2026 response.
Its first Bundibugyo trial is now enrolling
MBP134 paired with REGN3479 became the Bundibugyo outbreak's first authorised therapeutic intervention on 16 June 2026, six weeks after DRC and Uganda regulators received the application; the trial dosed its first patient on 2 July.
By 16 July, Africa CDC director-general Jean Kaseya said roughly 60 patients had enrolled across the MBP134, REGN3479 and obeldesivir arms combined, giving the trial its first public timeline: a readout around September or October. No efficacy or survival data has been published yet.